BAX
Baxter International Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
26.31
▼ 0.10 (0.38%)
MARKET · —
Price
Open
26.41
Prev close
26.41
Day high
26.67
Day low
26.09
Volume
3.08M
Market cap
$13.62B
P/E (TTM)
—
52W range
15.73 – 30.00
Trailing performance
Returnvs SPY
1W
-1.46%
-0.1%
1M
+21.55%
+17.8%
3M
+38.41%
+35.3%
6M
+22.06%
+11.0%
YTD
+37.83%
+25.5%
1Y
+8.53%
-11.5%
3Y
-37.40%
-111.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$13.62B
Enterprise value$21.11B
Revenue (TTM)$11.47B
Gross profit$3.91B
EBITDA$1.88B
Net income$-968.00M
EPS (TTM)$-1.88
Free cash flow$1.00B
Total cash$2.15B
Total debt$9.67B
Book value / share$12.00
Shares outstanding517.00M
Float514.51M
Short % of float9.97%
Dividend yield0.15%
Beta (5Y)0.60
Valuation & profitability ratios
Trailing P/E—
Forward P/E12.93
PEG ratio36.68
Price / sales—
Price / book2.19
EV / revenue1.84
EV / EBITDA11.20
Gross margin34.10%
Operating margin14.43%
Profit margin-9.27%
Return on equity-14.37%
Return on assets2.85%
Debt / equity156.45
Current ratio1.95
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $11.24B | $10.64B | $14.81B | $15.11B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$957.00M | -$649.00M | $2.66B | -$2.43B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$957.00M | -$649.00M | $2.66B | -$2.43B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.37 | 0.56 | +52.5% |
| Mar 2026 | 0.31 | 0.36 | +15.9% |
| Dec 2025 | 0.54 | 0.44 | -17.8% |
| Sep 2025 | 0.60 | 0.69 | +15.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.52 | 11 | $2.91B | +2.6% |
| Next quarter | 0.61 | 11 | $3.05B | +2.4% |
| Current year | 2.05 | 13 | $11.62B | +3.3% |
| Next year | 2.04 | 13 | $11.86B | +2.1% |
Analyst targets & ownership
Mean target$28.73
High target$40.00
Low target$23.00
Implied upside9.19%
Analyst count11
ConsensusHOLD
Strong buy / Buy1 / 1
Hold11
Sell / Strong sell0 / 0
Held by insiders0.34%
Held by institutions110.16%
Institutions holding954
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 1, 26 | ZIELINSKI ANITA A. Chief Financial Officer |
STOCK | 13.43K | $0 | Direct |
| May 5, 26 | AMPOFO WILLIAM A. II Director |
STOCK | 12.84K | $0 | Direct |
| May 5, 26 | WENDELL AMY MCBRIDE Director |
STOCK | 12.84K | $0 | Direct |
| May 5, 26 | SHAFER DAVID BRENT Chairman of the Board |
STOCK | 12.84K | $0 | Direct |
| May 5, 26 | MCDONNELL MICHAEL R Director |
STOCK | 12.84K | $0 | Direct |
| May 5, 26 | WILKES DAVID S. M.D. Director |
STOCK | 12.84K | $0 | Direct |
| May 5, 26 | SCHLICHTING NANCY M Director |
STOCK | 12.84K | $0 | Direct |
| May 5, 26 | CRAIG JEFFREY A Director |
STOCK | 12.84K | $0 | Direct |
| May 5, 26 | MORRISON PATRICIA B Director |
STOCK | 12.84K | $0 | Direct |
| Feb 27, 26 | ZIELINSKI ANITA A. Officer |
STOCK | 30.86K | $0 | Direct |
| Feb 27, 26 | ROSENBLOOM DAVID S General Counsel |
STOCK | 26.71K | $0 | Direct |
| Feb 27, 26 | HIDER ANDREW P Chief Executive Officer |
STOCK | 201.80K | $0 | Direct |
| Feb 27, 26 | CARLISLE CYNTHIA Officer |
STOCK | 29.68K | $0 | Direct |
| Feb 27, 26 | SORIANO MARIA CECILIA Officer |
STOCK | 23.74K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BORZI JAMES W |
Officer | 73.13K | Stock Award(Grant) |
GRADE JOEL T. |
Chief Financial Officer | 279.83K | Stock Award(Grant) |
HIDER ANDREW P |
Chief Executive Officer | 572.24K | Stock Award(Grant) |
KNIGHT HEATHER |
Chief Operating Officer | 177.36K | Stock Award(Grant) |
MASON JEANNE K |
Officer | 199.66K | Stock Award(Grant) |
RASUL REAZUR |
Officer | 139.85K | Stock Award(Grant) |
ROSENBLOOM DAVID S |
General Counsel | 144.84K | Stock Award(Grant) |
SHAFER DAVID BRENT |
Chairman of the Board | 72.80K | Stock Award(Grant) |
SONIG ALOK |
Officer | 130.30K | Stock Award(Grant) |
SORIANO MARIA CECILIA |
Officer | 77.89K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
26.74
-1.59% from price
SMA 20
26.55
-0.81% from price
SMA 50
23.60
+11.60% from price
SMA 100
20.83
+26.32% from price
SMA 200
19.95
+32.01% from price
EMA 12
26.45
-0.51% from price
EMA 26
25.58
+2.86% from price
EMA 50
24.02
+9.52% from price
RSI (14)
56.5
Neutral
MACD (12,26,9)
0.87
Hist -0.28
ATR (14)
0.88
3.34% of price
Realised vol 30D
47.3%
Annualised
Bollinger upper
29.00
20, 2σ
Bollinger lower
24.11
20, 2σ
50 / 200 cross
Golden
23.60 vs 19.95
Trend bias
Above 200
+32.01%
Risk profile
Beta vs SPY
1.17
More volatile than market
Correlation to SPY
0.35
Loosely linked
Realised vol 30D
47.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-36.0%
Peak to trough
Max drawdown 5Y
-82.3%
Peak to trough
ATR 14
0.88
3.34% of price
Beta (reported)
0.60
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.77
Call-heavy session
Put / call open interest
0.16
Positioning, not flow
Max pain
25.00
-5.1% from spot
ATM implied vol
61.9%
Nearest strike to spot
Skew (10% OTM)
-4.1%
Calls bid over puts
Call volume
326
Contracts, this expiry
Put volume
252
Contracts, this expiry
Heaviest call OI
31.00
1.24K contracts
Heaviest put OI
25.00
123 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
3 Unpopular Stocks That Fall Short
StockStory · 22h ago
Baxter hires new CFO with visa contingency
CFO Dive · 2d ago
Baxter hires CFO from Smith & Nephew
MedTech Dive · 2d ago
Baxter International Names John Rogers Chief Financial Officer
MT Newswires · 3d ago
Baxter Appoints John Rogers Chief Financial Officer
Business Wire · 3d ago
Baxter Reports Pricing of Upsized Cash Tender Offers
MT Newswires · 4d ago
Baxter Announces Pricing for Its Upsized Cash Tender Offers
Business Wire · 4d ago
COO Stock Surges 22% in Past Three Months: What's Driving the Uptrend?
Zacks · 4d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.